Company intelligence

ORGO

Organogenesis Holdings Inc. · NASDAQ · Healthcare

Price$1.00-9.94% · −$0.11

Market cap128.64MEquity value

P / E33.3Trailing ratio

Volume1.27MLatest session

Market data

ORGO price chart

TradingView

Related signals

1 min delayed

Browse public ORGO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ORGOApr 7, 2026+9.15% since signal

Organogenesis Achieves Key Trial Success, Stock Skyrockets Nearly 30%

Organogenesis has reported a successful trial for its PuraPly AM product, demonstrating significant wound closure at 12 weeks. Additionally, the FDA has approved the rolling BLA for ReNu, further enhancing investor confidence and driving the stock up nearly 30% during premarket trading.

View signal analysis

ORGOSep 26, 2025+5.30% since signal

Why Is Organogenesis Stock Trading Lower Friday?

ReNu failed to achieve primary endpoint in the second Phase 3 trial. Baseline pain reduction slightly improved but lacks statistical significance. Company plans to meet with FDA for BLA pathway discussions. ReNu has a favorable safety profile despite trial outcomes. ORGO shares fell 15.49% to $3.95 following the announcement.

View signal analysis

Research